Details of the Drug Combinations

General Information of This Drug (ID: DMWCQP4)

Drug Name
Interferon Alfa-2b   DMWCQP4
Synonyms Intron A; Viraferon
Indication
Disease Entry ICD 11 Status REF
Melanoma 2C30 Approved [1]
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug
Normalized Drug Combination Synergy Score
Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.
DrugCom Name DrugCom ID Component Drug Indication REF
Ribavirin + Interferon alfa-2B DCOUT2D Ribavirin Middle East Respiratory Syndrome (MERS) (Cell Line: .) [2]
------------------------------------------------------------------------------------
7 Clinical Trial Drug Combination(s) Consisting of This drug
DrugCom Name DrugCom ID Component Drug Indication REF
Bortezomib + Interferon alfa-2B DC1H6I8 Bortezomib Melanoma [3]
Celecoxib + Interferon alfa-2B DCEBYSW Celecoxib Malignant Neoplasm of Pancreas Metastatic to Peritoneal Surface [4]
Decitabine + Interferon alfa-2B DCW4NQD Decitabine Renal Cell Carcinoma [5]
Isotretinoin + Interferon alfa-2B DCH9EWH Isotretinoin Lymphoma, T-Cell [6]
Lovastatin + Interferon alfa-2B DC9VG9D Lovastatin Melanoma [7]
Sodium stibogluconate + Interferon alfa-2B DCX1HFP Sodium stibogluconate Advanced Cancer [8]
Entecavir + Interferon alfa-2B DCMIFY5 Entecavir Hepatitis B, Chronic [9]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 DrugCom(s)

References

1 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
2 SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol. 2016 Aug;14(8):523-34.
3 ClinicalTrials.gov (NCT01462773) Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma
4 ClinicalTrials.gov (NCT02151448) alphaDC1 Vaccine + Chemokine Modulatory Regimen (CKM) as Adjuvant Treatment of Peritoneal Surface Malignancies. U.S. National Institutes of Health.
5 ClinicalTrials.gov (NCT00561912) Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma
6 ClinicalTrials.gov (NCT00038376) Phase II Study Of Roferon and Accutane For Patients With T-Cell Malignancies
7 ClinicalTrials.gov (NCT00963664) Evaluation of Interferon-Lovastatin Therapy for Malignant Melanoma
8 ClinicalTrials.gov (NCT00629200) Sodium Stibogluconate With Interferon Alpha-2b for Patients With Advanced Malignancies
9 ClinicalTrials.gov (NCT02360592) Combination Therapy With Interferon Plus Interleukin 2 and Hepatitis B Vaccine in Chronic Hepatitis B Patients